These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20860662)

  • 1. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.
    De Forni D; Stevens MR; Lori F
    Br J Pharmacol; 2010 Oct; 161(4):830-43. PubMed ID: 20860662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.
    Lori F; De Forni D; Katabira E; Baev D; Maserati R; Calarota SA; Cahn P; Testori M; Rakhmanova A; Stevens MR
    PLoS One; 2012; 7(10):e47485. PubMed ID: 23094055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.
    Uglietti A; Maserati R
    Expert Opin Investig Drugs; 2011 Apr; 20(4):559-65. PubMed ID: 21391888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
    Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.
    Lori F; Foli A; Groff A; Lova L; Whitman L; Bakare N; Pollard RB; Lisziewicz J
    AIDS; 2005 Jul; 19(11):1173-81. PubMed ID: 15990570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
    López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
    AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
    Luzzati R; Di Perri G; Fendt D; Ramarli D; Broccali G; Concia E
    J Antimicrob Chemother; 1998 Oct; 42(4):565-6. PubMed ID: 9818769
    [No Abstract]   [Full Text] [Related]  

  • 8. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
    Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
    Sanne I; Smego RA; Mendelow BV
    Int J Infect Dis; 2001; 5(1):43-8. PubMed ID: 11285159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
    Kline MW; Calles NR; Simon C; Schwarzwald H
    Pediatr Infect Dis J; 2000 Nov; 19(11):1083-6. PubMed ID: 11099091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.
    Kakuda TN; Leopold L; Timmers M; Van De Casteele T; Hillewaert V; Tomaka FL; Hoetelmans RM
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):805-16. PubMed ID: 25109510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
    Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
    Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.
    Bakshi RP; Hamzeh F; Frank I; Eron JJ; Bosch RJ; Rosenkranz SL; Cramer YS; Ussery M; Flexner C
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1360-5. PubMed ID: 18184078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
    Ruxrungtham K; Kroon ED; Ungsedhapand C; Teeratakulpisarn S; Ubolyam S; Buranapraditkun S; van Leeuwen R; Weverling GJ; Kunanusont C; Lange JM; Cooper DA; Phanuphak P
    AIDS; 2000 Jul; 14(10):1375-82. PubMed ID: 10930152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.